More collaboration with Yale (AAU).
The University of Connecticut and UConn Health are partnering with Yale University to promote new business ventures that emerge from groundbreaking drug research.
Known as the Program in Innovative Therapeutics for Connecticut’s Health or PITCH, the initiative aims to translate basic science discoveries into therapeutic strategies that can be used to treat disease and improve human health. Licensing agreements associated with these new drug compounds will generate revenue for both universities. External investments in the new therapeutics will encourage the creation of biotech and biopharmaceutical start-up companies and jobs in Connecticut.
The initiative is supported by a three-year, $10 million investment by BioInnovation Connecticut, which helps innovators speed bioscience discoveries toward commercialization.
The effort will partner Yale’s Center for Molecular Discovery at the former Bayer pharmaceutical site in West Haven, Conn., with research cores at the UConn Storrs and UConn Health campuses to create a new, multi-centered statewide academic drug discovery consortium. Professors Crews, Wright, and Weller will lead teams at their respective campuses to identify and pursue possible leads in new drug discovery.
“This is the first time researchers from UConn and Yale have collaborated on such a large-scale project,” says Weller. “One of the most direct benefits will be increased productivity at both institutions thorough synergistic and collaborative efforts. Additional long-term benefits to the universities and the State of Connecticut come from the intellectual property embodied in the discoveries themselves.”
http://today.uconn.edu/2015/09/uconn-uconn-health-join-yale-on-10-million-drug-research-initiative/
The University of Connecticut and UConn Health are partnering with Yale University to promote new business ventures that emerge from groundbreaking drug research.
Known as the Program in Innovative Therapeutics for Connecticut’s Health or PITCH, the initiative aims to translate basic science discoveries into therapeutic strategies that can be used to treat disease and improve human health. Licensing agreements associated with these new drug compounds will generate revenue for both universities. External investments in the new therapeutics will encourage the creation of biotech and biopharmaceutical start-up companies and jobs in Connecticut.
The initiative is supported by a three-year, $10 million investment by BioInnovation Connecticut, which helps innovators speed bioscience discoveries toward commercialization.
The effort will partner Yale’s Center for Molecular Discovery at the former Bayer pharmaceutical site in West Haven, Conn., with research cores at the UConn Storrs and UConn Health campuses to create a new, multi-centered statewide academic drug discovery consortium. Professors Crews, Wright, and Weller will lead teams at their respective campuses to identify and pursue possible leads in new drug discovery.
“This is the first time researchers from UConn and Yale have collaborated on such a large-scale project,” says Weller. “One of the most direct benefits will be increased productivity at both institutions thorough synergistic and collaborative efforts. Additional long-term benefits to the universities and the State of Connecticut come from the intellectual property embodied in the discoveries themselves.”
http://today.uconn.edu/2015/09/uconn-uconn-health-join-yale-on-10-million-drug-research-initiative/
